FY2027 Earnings Estimate for IONS Issued By HC Wainwright

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($0.35) per share for the year. HC Wainwright has a “Buy” rating and a $120.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.18). The company had revenue of $203.33 million for the quarter, compared to the consensus estimate of $156.07 million. Ionis Pharmaceuticals had a negative net margin of 40.36% and a negative return on equity of 68.82%. The business’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.66) EPS.

IONS has been the subject of several other research reports. Wall Street Zen lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Barclays increased their price objective on shares of Ionis Pharmaceuticals from $95.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, January 22nd. Stifel Nicolaus boosted their target price on Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a “hold” rating in a research report on Thursday, February 26th. Finally, Piper Sandler upped their target price on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the company an “overweight” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.15.

Ionis Pharmaceuticals Stock Down 2.8%

NASDAQ IONS opened at $72.15 on Thursday. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $86.74. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of -29.57 and a beta of 0.31. The company has a fifty day moving average of $78.90 and a two-hundred day moving average of $75.63.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IONS. Capital World Investors lifted its holdings in shares of Ionis Pharmaceuticals by 41.2% during the fourth quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock worth $1,420,918,000 after purchasing an additional 5,238,571 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock worth $150,138,000 after buying an additional 2,724,400 shares during the period. Geode Capital Management LLC raised its position in Ionis Pharmaceuticals by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 3,148,849 shares of the company’s stock worth $249,158,000 after buying an additional 82,560 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Ionis Pharmaceuticals by 9.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,987,840 shares of the company’s stock valued at $236,370,000 after acquiring an additional 258,155 shares during the period. Finally, Tweedy Browne Co LLC lifted its stake in Ionis Pharmaceuticals by 0.3% during the 3rd quarter. Tweedy Browne Co LLC now owns 2,901,216 shares of the company’s stock valued at $189,798,000 after acquiring an additional 9,268 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Shannon L. Devers sold 44,199 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $85.08, for a total value of $3,760,450.92. Following the completion of the transaction, the executive vice president owned 17,494 shares of the company’s stock, valued at approximately $1,488,389.52. This trade represents a 71.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP C Frank Bennett sold 85,089 shares of Ionis Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $82.93, for a total transaction of $7,056,430.77. Following the sale, the executive vice president owned 80,293 shares of the company’s stock, valued at $6,658,698.49. The trade was a 51.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 1,035,882 shares of company stock valued at $80,492,247. 2.60% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $106 and maintained an “overweight” rating, arguing for roughly 45% upside from current levels — a near-term catalyst if investors follow the bank’s thesis. Barclays PT Raise
• Positive Sentiment: HC Wainwright reiterated a Buy rating and models FY2027 EPS of ($0.35) with a $120 price objective, signaling bullish institutional expectations for recovery and long-term value. HC Wainwright Report
• Positive Sentiment: Multiple independent broker notes (Needham, Barclays coverage summarized by financial outlets) point to strong upside and price appreciation potential based on portfolio progress and pipeline monetization. Needham Forecast
• Neutral Sentiment: Ionis repriced a drug ahead of a key FDA decision — a sign it’s positioning for a larger commercial market but also introduces execution risk if approval or launch dynamics differ from expectations. Monitor pricing, label and launch plans for impact. MSN Article
• Neutral Sentiment: Comparative analyses (Ionis vs. Innate Pharma) provide context but are unlikely to move the stock materially unless they reveal concrete partnership or competitive shifts. Head-to-Head Analysis
• Negative Sentiment: Zacks highlights that IONS is down since the last earnings release—investors remain concerned after the recent quarter showed a larger EPS miss, negative margins and revenue headwinds despite some revenue beats, keeping short-term sentiment pressured. Zacks Coverage

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.